Search research articles
Contact Us
Filters
Showing results (91-100 of 99) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 99 results.
European Urology
|
April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Evan Y Yu, Michael P Kolinsky, William R Berry, et al.
World Journal of Urology
|
April 3, 2014
Is there an anti-androgen withdrawal syndrome for enzalutamide?
Christoph A J von Klot, Mario W Kramer, Alena Böker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
The Lancet. Oncology
|
December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
Karim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Karim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albiges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
European Urology
|
November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines Committees
J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
European Urology
|
May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]
J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 99) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 99 results.
European Urology
|
April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Evan Y Yu, Michael P Kolinsky, William R Berry, et al.
World Journal of Urology
|
April 3, 2014
Is there an anti-androgen withdrawal syndrome for enzalutamide?
Christoph A J von Klot, Mario W Kramer, Alena Böker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
The Lancet. Oncology
|
December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
Karim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Karim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albiges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
European Urology
|
November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines Committees
J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
European Urology
|
May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]
J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Page
of 10